You’ve got to feel for
Richard Kronick, professor of family and preventive medicine at the University of California San Diego. His
Health Affairs “
2009 article of the year” uncovered unexpected news about the relationship between U.S. health coverage and mortality.
“It was not the answer I wanted,” the former Clinton administration health policy advisor told
Politifact.com at the height of last summer’s health reform debate. He added that he might lose a few friends over the work. Even so, he
was appointed Health and Human Services deputy secretary of health policy in January 2010.
Dr. Kronick’s findings contradict a 2002
Institute of Medicine (IOM)
estimate that uninsurance leads to 18,000 excess deaths annually. Published online last April, his paper concluded that extending insurance coverage to all adults would do little to reduce U.S. deaths.
The work was lauded for wisely adjusting data for demographic and health factors, a step the IOM panel didn’t take. Dr. Kronick showed no difference in the risk of subsequent mortality for uninsured respondents than for those covered by employer-sponsored group insurance.
In other words, while health insurance is necessary, just providing coverage to more Americans alone offers no magic fixes. A sedentary smoker with diabetes is equally likely to die prematurely if insured as uninsured. Simply carrying an active insurance card will not control your blood sugar, help you stop smoking, or motivate you to get moving.
What can make a difference, however, is getting care that actually prevents illness, effectively treats acute injuries and illnesses, and improves chronic conditions. As health reform takes hold, we need much better evidence about the elements of such care and how to deliver it efficiently and effectively to an influx of previously uninsured patients. “Rescue care” at hospital emergency departments may have kept the uninsured alive, but they are living with a higher burden of chronic illness. And rescue care is costly and not very effective anyway. To make good care accessible and affordable for all, we must eliminate waste and invest resources in care that truly improves health.
The National Institutes of Health (
NIH), through its Director
Francis Collins, intends to address these kinds of issues in its newly conceived
HMO Collaboratory. This will be a national population laboratory comprising 15 U.S. health plans of the HMO Research Network (
HMORN), including Group Health. The HMORN includes more than 350 multidisciplinary scientists studying 13 million covered individuals.
Dr. Collins approached the HMORN leadership early this year to explore forming the HMO Collaboratory because he wants the nation’s research infrastructure to speed up comparative effectiveness research (
CER)—which is best conducted in large, real-world patient-care settings like the HMORN health plans. The Collaboratory can leverage the Network’s “learning health care systems”—where research and practice influence each other.
Dr. Collins values the HMORN’s 16-year history of successful collaboration in multi-site, NIH-funded research on cancer control, cardiovascular health, immunization, drug safety, and so on. His idea is to infuse the HMORN with new resources so it can address more topics, expand its data capabilities, and involve new partners and scientists in its research. This is breaking new ground not only for the HMORN but also for NIH, which traditionally contributes knowledge but aspires to do more improvement.
NIH informed Group Health Research Institute (GHRI) in late June that the HMORN could apply for a one-year $1 million administrative supplement to plan for and establish the Collaboratory. This supplement was assembled in three weeks’ time and submitted on July 31. GHRI will take the lead in the Collaboratory; I will serve as principal investigator,
Sarah Greene as managing director, and
Ella Thompson as project manager. We will also plan to name a business manager and an administrative coordinator for the project. We are proposing a Collaboratory Council comprising the GHRI team plus four to six investigators from various HMORN sites. We will also identify co-leads for the major scientific areas of the Collaboratory (large-scale epidemiology, health care delivery research, and clinical trials).
The HMO Collaboratory is an ambitious undertaking for GHRI and our HMORN partners. But other network leaders and I agree this extraordinary opportunity comes at an unprecedented time in the evolution of the nation’s health care system. We are committed to putting our best effort forward.
Recent Comments